| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5396826ac8c36d31e3eb53c9ef088a68 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5089
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30 |
| filingDate |
2014-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_062df14341b5d91577a93c8e159b103c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc71131a9fc201354c3b3aa072c1c966
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42a3c9b83978c6cd6555cad26ab687d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c598419c3ed456432a089dee32e32a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86a6ccc1280040a9cf897ad0d1aa7c23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44992e6a48b8ab364766eed450b00351
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aeeca18dd875c7f317583bbee78c6ee2 |
| publicationDate |
2016-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20160020625-A |
| titleOfInvention |
Immediate release oral composition comprising non-steroidal anti-inflammatory drug and proton pump inhibitor, and method for preparing the same |
| abstract |
The present invention relates to an inner capsule comprising a non-steroidal anti-inflammatory drug (NSAID) and a proton pump inhibitor (PPI); And an outer capsule comprising an alkaline buffer and surrounding the inner capsule, wherein the composition of the present invention is configured in the form of a double capsule encapsulating the outer part with an alkaline buffer so that the pH of the gastric environment To increase the solubility of the pH-dependent drug, and to improve the solubility and dissolution of the drug by converting the crystalline form of the drug into an amorphous form, so that the drug can be effectively used as a rapid-acting composition without being affected by pH. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019240310-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023033455-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11759428-B2 |
| priorityDate |
2014-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |